You just read:

Bexion Pharmaceuticals Experiences Robust Enrollment of Phase I Part 3 First-In-Human Trial Using BXQ-350 for the Treatment of Cancer

News provided by

Bexion Pharmaceuticals, Inc.

Mar 05, 2019, 09:07 ET